Prosecution Insights
Last updated: April 19, 2026

Aquestive Therapeutics, Inc.

10 pending office actions

Portfolio Summary

10
Total Pending OAs
3
Final Rejections
7
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18413556 ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS SCHLIENTZ, NATHAN W 1616 Final Rejection Jan 16, 2024
17971282 PHARMACEUTICAL COMPOSITIONS WITH ENHANCED STABILITY PROFILES LIPPERT, JOHN WILLIAM 1615 Non-Final OA Oct 21, 2022
17691107 DOSAGE FORMS HAVING EQUIVALENT BIOCOMPARABLE PROFILES KIM, DANIELLE A 1613 Final Rejection Mar 09, 2022
17576923 PRODRUG COMPOSITIONS AND METHODS OF TREATMENT SEAMAN, D MARGARET M 1625 Non-Final OA Jan 15, 2022
17549219 ENHANCED DELIVERY EPINEPHRINE AND PRODRUG COMPOSITIONS SCHLIENTZ, NATHAN W 1616 Final Rejection Dec 13, 2021
17098324 MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT THOMAS, TIMOTHY P 1614 Non-Final OA Nov 14, 2020
17086409 PRODRUG COMPOSITIONS AND METHODS OF TREATMENT HUI, SAN MING R 1627 Non-Final OA Nov 01, 2020
17031207 SUBLINGUAL AND BUCCAL FILM COMPOSITIONS ABUZEINEH, HANAN ISAM 1633 Non-Final OA Sep 24, 2020
16143678 PHARMACEUTICAL COMPOSITIONS WITH ENHANCED PERMEATION YOUNG, MICAH PAUL 1618 Non-Final OA Sep 27, 2018
16143036 DELIVERY PHARMACEUTICAL COMPOSITIONS INCLUDING PERMEATION ENHANCERS PHAN, DOAN THI-THUC 1613 Non-Final OA Sep 26, 2018

Managing Aquestive Therapeutics, Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month